Rabz 20mg Tab is used for the treatment of stomach and intestinal ulcers. The active ingredient contained in RABZ is Rabeprazole Sodium which is a substituted benzimidazole that inhibits gastric acid secretion.
PHARMACODYNAMICS
Mechanism of Action:
Rabeprazole Sodium belongs to a class of anti-secretory compounds (substituted benzimidazole proton-pump inhibitors) that suppress gastric acid secretion by inhibiting the gastric H+K+ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, Rabeprazole Sodium has been characterized as a gastric proton-pump inhibitor. Rabeprazole Sodium blocks the final step of gastric acid secretion. In gastric parietal cells Rabeprazole Sodium is protonated, accumulates and is transformed into an active Sulfonamide.
Anti-secretory Activity:
The anti-secretory effect begins within one hour after oral administration of 20mg Rabeprazole Sodium (RABZ). In patients with gastroesophageal reflux disease (GERD) and moderate to severe esophageal acid exposure, Rabeprazole Sodium (RABZ) 20mg per day decreases 24 hour esophageal acid exposure.
INDICATIONS OF TABLET:
Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD):
Rabeprazole Sodium (RABZ) is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8 week course of Rabeprazole Sodium (RABZ) may be considered. Rabeprazole Sodium (RABZ) is indicated for maintaining healing and reducing relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD maintenance).
Duodenal Ulcers:
Rabeprazole Sodium (RABZ) is indicated for short-term (up to 4 weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Mostly patients heal within 4 weeks.
Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome:
Rabeprazole Sodium (RABZ) is indicated for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.
Storage: Store in a cool and dry place
Habit Forming: No
Sedation: No
Child Safety: No
Route of Administration: Oral